ONLINE DATABASE SEARCH - HIV-LS-330-MEMO
1. 47820 HIV-LS-330; PUBMED-HIV-9/6/2005
Antimicrobial Peptides from Amphibian Skin Potently Inhibit Human Immunodeficiency Virus Infection and Transfer of Virus from Dendritic Cells to T Cells
Vancompernolle, SE, Taylor, RJ, Oswald-Richter, K, Jiang, J, Youree, BE, Bowie, JH, Tyler, MJ, Conlon, JM, Wade, D, Aiken, C, Dermody, TS, Kewalramani, VN, Rollins-Smith, LA, and Unutmaz, D
J Virol 2005. 79(18): 11598-11606
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16140737&dopt=abstract
2. 47821 HIV-LS-330; PUBMED-HIV-9/6/2005
Two new sesquiterpenoids and anti-HIV principles from the root bark of Zanthoxylum ailanthoides
Cheng, MJ, Lee, KH, Tsai, IL, and Chen, IS
Bioorg Med Chem 2005.
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16140017&dopt=abstract
3. 47822 HIV-LS-330; EMBASE-HIV-9/6/2005
4-Phenylcoumarins as HIV transcription inhibitors
Bedoya, Luis M, Beltran, Manuela, Sancho, Rocio, Olmedo, Dionisio A, Sanchez-Palomino, Sonsoles, del Olmo, Esther, Lopez-Perez, Jose L, Munoz, Eduardo, Feliciano, Arturo San, and Alcami, Jose
Bioorganic & Medicinal Chemistry Letters 2005. In Press, Corrected Proof
HYPERLINK:
http://www.sciencedirect.com/science/article/B6TF9-4H0J8H5-5/2/473bd743477fc084218d83a6e44d06cd
4. 47823 HIV-LS-330; PUBMED-HIV-9/6/2005
4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants
Tanaka, H, Haraguchi, K, Kumamoto, H, Baba, M, and Cheng, YC
Antivir Chem Chemother 2005. 16(4): 217-21
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16130520&dopt=abstract
5. 47824 HIV-LS-330; PUBMED-HIV-9/6/2005
High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target
Cao, J, Isaacson, J, Patick, AK, and Blair, WS
Antimicrob Agents Chemother 2005. 49(9): 3833-41
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16127060&dopt=abstract
6. 47825 HIV-LS-330; PUBMED-HIV-9/6/2005
An anti-HIV microbicide comes alive
Lagenaur, LA and Berger, EA
Proc Natl Acad Sci U S A 2005. 102(35): 12294-5
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16118279&dopt=abstract
7. 47826 HIV-LS-330; PUBMED-HIV-9/6/2005
Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives
Bal, TR, Anand, B, Yogeeswari, P, and Sriram, D
Bioorg Med Chem Lett 2005.
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16115762&dopt=abstract
8. 47827 HIV-LS-330; PUBMED-HIV-9/6/2005
Synthesis and antiviral evaluation of novel methyl branched cyclopropyl phosphonic acid nucleosides
Kim, JW, Ko, OH, and Hong, JH
Arch Pharm Res 2005. 28(7): 745-9
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16114485&dopt=abstract
9. 47828 HIV-LS-330; PUBMED-HIV-9/6/2005
Anti-HIV activity of dibenzylbutyrolactone-type lignans from Phenax species endemic in Costa Rica
Piccinelli, AL, Mahmood, N, Mora, G, Poveda, L, De, Simone F, and Rastrelli, L
J Pharm Pharmacol 2005. 57(9): 1109-16
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16105232&dopt=abstract
10. 47829 HIV-LS-330; PUBMED-HIV-9/6/2005
ANTI-AIDS AGENTS 65: INVESTIGATION OF THE IN VITRO OXIDATIVE METABOLISM OF 3',4'-DI-O-(-)-CAMPHANOYL-(+)-CIS-KHELLACTONE (DCK) DERIVATIVES AS POTENT ANTI-HIV AGENTS
Suzuki, M, Li, Y, Smith, PC, Swenberg, JA, Martin, DE, Morris-Natschke, SL, and Lee, KH
Drug Metab Dispos 2005.
HYPERLINK:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16087699&dopt=abstract
11. 47830 HIV-LS-330; EMBASE-HIV-9/6/2005
Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1
Krebs, Fred C, Miller, Shendra R, Ferguson, Mary Lee, Labib, Mohamed, Rando, Robert F, and Wigdahl, Brian
Biomedecine & Pharmacotherapy 2005. In Press, Uncorrected Proof
HYPERLINK:
http://www.sciencedirect.com/science/article/B6VKN-4GX1P40-1/2/4dc11309bda3f5ec82595725968edb5a
12. 47831 HIV-LS-330; EMBASE-HIV-9/6/2005
Polysulfated sialic acid derivatives as anti-human immunodeficiency virus
Terada, Masaki, Fujita, Shuji, Suda, Isao, and Mastico, Robert
Biomedecine & Pharmacotherapy 2005. In Press, Corrected Proof
HYPERLINK:
http://www.sciencedirect.com/science/article/B6VKN-4GVH2GS-1/2/cfd9e43117ab7c4aef5602bc56d07269
13. 47832 HIV-LS-330; WOS-HIV-8/28/2005
Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1
Espert, L, Degols, G, Lin, YL, Vincent, T, Benkirane, M, and Mechti, N
JOURNAL OF GENERAL VIROLOGY 2005. 86: 2221-2229, 9
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000231033300011
14. 47833 HIV-LS-330; WOS-HIV-8/28/2005
Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens
Pashov, A, Canziani, G, Monzavi-Karbassi, B, Kaveri, SV, MacLeod, S, Saha, R, Perry, M, VanCott, TC, and Kieber-Emmons, T
JOURNAL OF BIOLOGICAL CHEMISTRY 2005. 280(32): 28959-28965, 7
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000231021300017
15. 47834 HIV-LS-330; WOS-HIV-8/28/2005
The 3 '-azido group is not the primary determinant of 3 '-azido-3 '-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1
Sluis-Cremer, N, Arion, D, Parikh, U, Koontz, D, Schinazi, RF, Mellors, JW, and Parniak, MA
JOURNAL OF BIOLOGICAL CHEMISTRY 2005. 280(32): 29047-29052, 6
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000231021300029
16. 47835 HIV-LS-330; WOS-HIV-8/28/2005
Anti-HIV natural products
Singh, IP, Bharate, SB, and Bhutani, KK
CURRENT SCIENCE 2005. 89(2): 269-290, 22
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000230981300022
17. 47836 HIV-LS-330; WOS-HIV-8/28/2005
Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist
Takashima, K, Miyake, H, Kanzaki, N, Tagawa, Y, Wang, X, Sugihara, Y, Iizawa, Y, and Baba, M
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2005. 49(8): 3474-3482, 9
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000230950700054
18. 47837 HIV-LS-330; WOS-HIV-9/4/2005
Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo
Ho, CC, Lin, SS, Chou, MY, Chen, FL, Hu, CC, Chen, CS, Lu, GY, and Yang, CC
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2005. 56(2): 372-379, 8
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000231094000022
19. 47838 HIV-LS-330; WOS-HIV-9/4/2005
Prospects for the resistance to HIV protease inhibitors: Current drug design approaches and perspectives
Burlet, S, Pietrancosta, N, Laras, Y, Garino, C, Quelever, G, and Kraus, JL
CURRENT PHARMACEUTICAL DESIGN 2005. 11(24): 3077-3090, 14
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000231229700002
20. 47839 HIV-LS-330; WOS-HIV-9/4/2005
A once-daily HAART regimen containing indinavir plus ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)
Burger, DM, Aarnoutse, RE, Dieleman, JP, Gyssens, IC, Nouwen, J, de, Marie S, Koopmans, PP, Stek, M, and van, der Ende ME
ANTIVIRAL THERAPY 2003. 8(5): 455-461, 7
HYPERLINK:
http://publishorperish.nih.gov/Gateway.cgi?KeyUT=000231266700012